- Home
- ITIC vs MIST Comparison
ITIC vs MIST Comparison
Compare ITIC & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ITIC | MIST |
|---|---|---|
| Founded | 1972 | 2003 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 517.1M | 163.2M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ITIC | MIST |
|---|---|---|
| Price | $251.96 | $2.07 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 18.5K | ★ 10.0M |
| Earning Date | 02-12-2026 | 11-12-2025 |
| Dividend Yield | ★ 6.29% | N/A |
| EPS Growth | ★ 25.81 | N/A |
| EPS | ★ 19.00 | N/A |
| Revenue | ★ $273,864,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $13.26 | ★ N/A |
| Revenue Growth | ★ 13.63 | N/A |
| 52 Week Low | $190.20 | $0.63 |
| 52 Week High | $288.98 | $3.06 |
Technical Indicators
Market Signals| Indicator | ITIC | MIST |
|---|---|---|
| Relative Strength Index (RSI) | 44.53 | 41.82 |
| Support Level | $250.26 | $2.00 |
| Resistance Level | $260.66 | $2.22 |
| Average True Range (ATR) | 7.32 | 0.32 |
| MACD | 0.30 | -0.08 |
| Stochastic Oscillator | 51.41 | 31.72 |
Price Performance
Historical ComparisonAbout ITIC Investors Title Company
Investors Title Co operates in the title insurance and exchange services sectors. The title insurance segment, conducted through ITIC and NITIC, offers title insurance policies for residential, commercial, and industrial properties in around 22 states and the District of Columbia, with a focus on the eastern United States. The title insurance segment issues title insurance policies through approved attorneys from underwriting offices and through independent issuing agents. Title insurance policies insure titles to real estate.n The Title Insurance segment contributes the majority of the company's revenue.
About MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).